Related Experiment Video
Updated: Jun 19, 2025
03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
394
Osteopontin: A Key Multifaceted Regulator in Tumor Progression and Immunomodulation
Venketesh K Panda1, Barnalee Mishra1, Angitha N Nath1
1School of Biotechnology, KIIT Deemed to be University, Bhubaneswar 751024, India.
Biomedicines
|July 27, 2024
Summary
Osteopontin (OPN) drives cancer progression and impacts treatment outcomes in breast cancer. Targeting OPN offers a promising strategy for improved cancer therapy and patient prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Biology
Background:
- The tumor microenvironment (TME) comprises diverse cellular elements influencing tumor growth, metastasis, and treatment resistance.
- Current breast cancer therapies face challenges with toxicity and non-specific side effects, necessitating improved drug delivery and efficacy.
- Osteopontin (OPN) is increasingly recognized for its role in various cancers, including breast cancer.
Purpose of the Study:
- To review the multifaceted roles of osteopontin (OPN) in regulating cancer progression.
- To elucidate the signaling pathways involving OPN, integrins, and CD44 receptors in tumor biology.
- To explore OPN's involvement in tumor-stromal interactions, epithelial-mesenchymal transition (EMT), cancer stem cell (CSC) enhancement, immunomodulation, metastasis, chemoresistance, and metabolic reprogramming.
Main Methods:
- Literature review of studies on osteopontin (OPN) in cancer.
- Analysis of OPN's interactions with cellular receptors like integrins and CD44.
- Examination of OPN's influence on key cancer hallmarks and therapeutic responses.
Main Results:
- Osteopontin (OPN), derived from both tumor and stromal cells, significantly contributes to the oncogenic potential of breast cancer.
- OPN signaling through integrins and CD44 receptors promotes tumor progression, EMT, CSCs, and metastasis.
- OPN plays a critical role in modulating the immune response within the TME and confers chemoresistance and metabolic reprogramming.
Conclusions:
- Osteopontin (OPN) is a key regulator of tumor progression and influences multiple aspects of cancer biology, including metastasis and treatment resistance.
- OPN's involvement in tumor-stromal interactions and its impact on the immune microenvironment highlight its significance.
- Osteopontin (OPN) presents a potential therapeutic target and prognostic biomarker for enhancing breast cancer management and patient outcomes.
Keywords:
cancercancer-associated fibroblastsimmunomodulationosteopontin (OPN)single cell transcriptomicstargeted therapytumor-associated macrophagesMore Related Videos
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
7.5K
06:00Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
7.1K
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
01:27Tumor Immunotherapy
498
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
498
01:19Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K